Evidence map›Paper›PMID 42519326›Full record

ReviewFrontiers in immunology2026

Cell cycle dysregulation: a central hub in colitis-associated colorectal carcinogenesis.

Yuanjie Fu, Ying Wang, Shunjing Wu, Yi Ying, Junxin Li, Yanghuan Ou, Yinying Wang, Li Li, Yueying Wu, Jinyuan Yan and 1 more

Erratum issuedAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Yuanjie Fu *Yunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China.
Ying Wang *Yunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China.
Shunjing WuYunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China.
Yi YingArtemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Junxin LiYunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China.
Yanghuan OuYunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China.
Yinying WangYunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China.
Li LiYunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China.
Yueying WuYunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China.
Jinyuan YanCenter Laboratory of the Second Hospital Affiliated, Kunming Medical University, Kunming, China.
Zhongshan YangYunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The process of developing from inflammatory bowel disease (IBD) to colorectal cancer (CRC) depends on the dysregulation of the core cell cycle network. Single-cell omics studies have revealed a significant difference: malignant colorectal cancer cells are mainly in the G2/M phase, while epithelial cells in inflammatory bowel disease (IBD) exhibit G1 phase arrest or excessive proliferation - this indicates that during chronic inflammation, the original cell cycle of precancerous cells has already become dysregulated. Among the key signaling pathways, such as Rb-E2F, NF-κB, JAK-STAT and Hippo-YAP, jointly regulate the cell cycle system. Including cyclins D1, A2 and B1 and their cyclin-dependent kinases (CDKs), as well as cyclin-dependent kinase inhibitors (such as p21, p27, p57), jointly regulate intestinal tumor cells and tumor immune escape. Therefore, this review elaborates on the key interactions between ROS and the cell cycle/cyclin/CDK axis, and explains in detail how oxidative stress and DNA damage disrupt cell cycle checkpoints, thereby driving the growth, invasion, metastasis and immune escape of intestinal tumors. In conclusion, for the regulation of the cell cycle during the "inflammation-cancer" transformation process in colorectal cancer, new targets and reasonable combination strategies have been proposed.

Indexed as

CarcinogenesisCell CycleColitisColitis-Associated NeoplasmsColorectal NeoplasmsAnimalsCell Transformation, NeoplasticDNA DamageHumansOxidative StressReactive Oxygen SpeciesSignal TransductionReactive Oxygen Speciescell cyclecolorectal “inflammation-cancer” transformationcyclin-dependent kinase inhibitorsHippo–YAP pathwayoxidative stress

Identifiers

PMID42519326
PMCPMC13381311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.